“It is critical to have grass-roots experimentation,” says Bruno Villetelle, chief digital officer at Takeda Pharmaceuticals. “We set up an internal digital accelerator and innovation fund to stimulate this, and we run a regular Dragons’ Den competition to identify and fund development and ...
More recently, Inovio threw its hat into the Zika virus ring along with big pharmas with billions in revenue such asSanofiandTakeda. Last August it began a 160 patient study with GLS-5700 that should have top-line data ready in June. Although 160 patients is awfully small for a vaccine ...
SG reports personal fees from Lundbeck, Janssen, Sunovion, Gedeon Richter-Recordati, and Angelini; and has consulted or served on advisory boards for Millennium Pharmaceuticals, Innova Pharma-Recordati Group, Janssen, Gedeon Richter-Recordati, and Angelini; and non-financial support from Gedeon Richter...
Space is at its tipping point of technology readiness, like aviation was before manufacturing became lean and operations streamlined for big scale projects. Soon, the cost to fly to the Moon could go from $75 million to as little as $100,000, according to Space Adventures (Becker 2017). ...
Vimovo is unique in that it combines a PPI with a pain reliever. It contains the active ingredients of both Nexium (esomeprazole) and Aleve (naproxen). It is also the most expensive proton pump inhibitor in the U.S. According toCNN, a month’s supply of the prescription drug cost more...
and this huge R&D budget, to come and work for PepsiCo in consumer products, with such a tiny budget?” I said, “Mehmood, the big difference is in PepsiCo, you can make change on a large-scale basis, and you can taste every product you make,” which you cannot in pharmaceuticals....
6 GSK Annual Report 2014 Pharmaceuticals Our Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Our portfolio is made up of innovative and established medicines and we have leading global positions in respiratory disease and HIV. Read more on...
s who now works in private equity and venture capital, joined us at a large folding table. Krenteras and Menon were discussing how to draw users to an open-source platform for pharmaceuticals, how to sustain such an operation financially, and how to convince Big Pharma to participate and ...